CLINICAL TRIALS PROFILE FOR ZONTIVITY

All Clinical Trials for ZONTIVITY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02394730 ↗	Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints	Completed	Merck Sharp & Dohme Corp.	Phase 1/Phase 2	2015-09-01	ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.
NCT02394730 ↗	Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1/Phase 2	2015-09-01	ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.
NCT02394730 ↗	Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints	Completed	University of Melbourne	Phase 1/Phase 2	2015-09-01	ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.
NCT02394730 ↗	Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints	Completed	University of Minnesota	Phase 1/Phase 2	2015-09-01	ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.
NCT02394730 ↗	Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 1/Phase 2	2015-09-01	ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.

Clinical Trial Conditions for ZONTIVITY

Condition Name

Condition Name for ZONTIVITY
Intervention	Trials
Myocardial Infarction	2
Peripheral Artery Disease	1
AV Fistula	1
Diabetes Mellitus	1

Condition MeSH

Condition MeSH for ZONTIVITY
Intervention	Trials
Myocardial Infarction	2
Infarction	2
Peripheral Arterial Disease	2
Diabetes Mellitus	1

Clinical Trial Locations for ZONTIVITY

Trials by Country

Trials by Country for ZONTIVITY
Location	Trials
United States	5
Australia	2

Trials by US State

Trials by US State for ZONTIVITY
Location	Trials
Florida	2
California	1
Minnesota	1
Maryland	1

Clinical Trial Progress for ZONTIVITY

Clinical Trial Phase

Clinical Trial Phase for ZONTIVITY
Clinical Trial Phase	Trials
Phase 4	3
Phase 2	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for ZONTIVITY
Clinical Trial Phase	Trials
Completed	4
Withdrawn	1

Clinical Trial Sponsors for ZONTIVITY

Sponsor Name

Sponsor Name for ZONTIVITY
Sponsor	Trials
Merck Sharp & Dohme Corp.	5
University of Florida	2
University of Minnesota - Clinical and Translational Science Institute	1

Sponsor Type

Sponsor Type for ZONTIVITY
Sponsor	Trials
Other	10
Industry	5
NIH	1

Last updated: May 1, 2026

ZONTIVITY (vorapaxar): Clinical Trials Update, Market Analysis, and Projection

What is ZONTIVITY and how is it positioned commercially?

ZONTIVITY is vorapaxar, an oral antagonist of the protease-activated receptor-1 (PAR-1), approved for reduction of cardiovascular (CV) events in defined secondary-prevention populations.

Label scope (US):

• Indication: reduction of CV events in patients with prior myocardial infarction (MI) or multivessel coronary artery disease with a history of MI (per current FDA labeling language).
• Key safety limiting factor: intracranial hemorrhage (ICH) risk, which drives constrained use versus broad antiplatelet strategies.

Commercial implication: The product’s penetration is structurally limited by (1) high-risk bleeding profile versus standard-of-care antiplatelets, and (2) narrowing of eligible cohorts under real-world GI bleed and ICH concerns, along with guideline evolution toward other agents and strategies.

---

What does the clinical trials landscape look like for vorapaxar?

Vorapaxar development and lifecycle activity is best understood in three phases: (1) pivotal efficacy trials, (2) safety-led contraction after ICH signals, and (3) subsequent studies that largely targeted narrower hypotheses (often in combination or in specific vascular cohorts).

1) Core efficacy evidence used for approval

The pivotal dataset anchors on:

• TRACER (secondary prevention in atherosclerotic disease; trial evaluated vorapaxar in acute coronary syndrome contexts)
• TRA 2°P–TIMI 50 (secondary prevention, including post-MI and polyvascular disease segments)

These trials established efficacy in reducing ischemic events but also established the ICH risk profile that became a key determinant of on-label constraints.

Safety consequence: After ICH risk was fully characterized, the program shifted toward limiting use in populations at highest bleeding risk, and it did not transition into a broad replacement for standard antiplatelet regimens.

2) Post-approval trial posture

Post-approval activity for vorapaxar has been comparatively limited relative to peers. The dominant pattern has been:

• studies aiming at mechanistic add-ons or subgroup benefit rather than large-scale replacement of SOC,
• trials and analyses that focus on bleeding risk mitigation and patient selection.

Current state (practical market effect):

• No sustained pipeline signal indicates a near-term “new indication” expansion on the scale needed to restore pre-ICH-era adoption.
• The clinical relevance now depends primarily on guideline-permitted use in narrower subsets and on the availability of alternative antiplatelet options with more favorable net clinical benefit in routine practice.

---

How should ZONTIVITY’s competitive environment be read for market outlook?

Vorapaxar competes in the antiplatelet class but does not compete like a typical “same mechanism” product, because its PAR-1 antagonism positions it against:

• P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor),
• aspirin combinations and bleeding-moderated dual antiplatelet therapy (DAPT) strategies,
• and, in many segments, newer approaches that reduce bleeding risk through regimen duration, selection, and alternative targets.

Where vorapaxar wins

• Patients where PAR-1 blockade adds incremental ischemic benefit without unacceptable bleeding risk under label constraints.
• Secondary prevention subpopulations where clinicians are willing to manage bleeding risk carefully.

Where vorapaxar loses

• Routine post-ACS and post-PCI pathways where practice gravitates to P2Y12 inhibitors with strong evidence and established protocols.
• Older patients, prior stroke/TIA cohorts, and any population where ICH risk becomes operationally prohibitive.

Real-world constraint drivers

• ICH risk reduces willingness to prescribe.
• Regimen complexity and incremental benefit uncertainty versus SOC reduces adoption outside label-safe subsets.
• Competing antithrombotics have broader guideline coverage and more common prescribing workflows.

---

What is the likely market scale and adoption ceiling?

A precise current market number requires proprietary claims and sales datasets. Since the only robust market sizing that can be cited here would need those datasets, the actionable view for investment and R&D planning is to frame adoption through structural ceiling conditions:

Adoption ceilings

Vorapaxar adoption is likely capped by:

• Eligibility: label-protected subsets only.
• Safety logistics: ICH risk requires stricter selection, baseline risk screening, and careful monitoring.
• Therapeutic substitution: clinicians default to P2Y12 inhibitor-based strategies where bleeding concerns can be managed via duration and selection.

Penetration pattern expectation

• Penetration growth from current levels is unlikely to be broad-based.
• Any incremental growth would likely be driven by guideline or formulary shifts that explicitly expand use, or by improvements in patient selection and adherence to label safety exclusions.

---

What are the drivers of future revenue trajectory?

1) Patient selection and guideline adherence

Net revenue performance depends on whether prescribers keep vorapaxar within the safest label interpretation. Tight adherence protects outcomes but caps volume.

2) Competitive switching from evolving antiplatelet regimens

Shifts in real-world practice toward:

• more personalized DAPT duration,
• preferential selection of specific P2Y12 inhibitors,
• and procedural antithrombotic pathways, reduce opportunities for PAR-1 antagonists to gain share.

3) Patent and lifecycle economics

ZONTIVITY’s revenue durability depends on:

• remaining exclusivity windows and patent estates (not addressed here with source-backed dates),
• and whether biosimilar-like substitution analogs exist (they do not apply here),
• or whether generics erode pricing (not quantified here without dated sources).

---

Market projection for ZONTIVITY: base case, not a high-growth profile

Because a high-quality numeric projection requires dated pricing, sales, market size, and exclusivity schedules with citations, the most decision-grade projection that can be stated without inventing numbers is directional.

Base case (directional)

• Revenue trends: stable to declining over the projection horizon if no label expansion or compelling new evidence changes benefit-risk perception.
• Volume: slowly declining or flat as competing standards dominate.
• Pricing: modest erosion likely if competitive pressures increase or if generic entry occurs.

Bull case

• A clear re-framing in clinical practice that improves net clinical benefit perception in specific subgroups.
• Meaningful formulary adoption in integrated secondary prevention programs.
• Evidence for additional combination strategies with managed bleeding risk.

Bear case

• Further guideline contraction of PAR-1 antagonist usage based on bleeding risk management trends.
• Persistent prescribing reluctance due to ICH risk.
• Accelerating substitution to preferred P2Y12-based regimens and regimen simplification.

---

Key metrics investors should track (operational scoreboard)

1. Script volume by indication cohort (post-MI vs broader vascular indications within label language).
2. Bleeding and ICH-related safety signals in routine care (pharmacovigilance outcomes and label compliance).
3. Formulary status and payer utilization (commercial and Medicare Part D restrictions).
4. Competitive regimen shift in cardiology practice (DAPT duration and selection of P2Y12 inhibitor).
5. Lifecycle timeline (exclusivity and patent milestones impacting pricing and unit sales).

---

Key Takeaways

• ZONTIVITY (vorapaxar) has a constrained commercial profile because PAR-1 blockade comes with an intracranial hemorrhage risk that limits eligible patient populations.
• The clinical evidence supports ischemic event reduction, but the safety profile has driven narrower use patterns and reduced expansion potential.
• Market upside is structurally limited by dominant SOC antiplatelet strategies and ongoing guideline/payer pressure favoring regimens with more favorable net clinical benefit in routine use.
• The most decision-grade projection is stable-to-declining revenue directionality unless new, well-cited evidence expands label-safe cohorts or changes prescribing behavior materially.

---

FAQs

1) What is vorapaxar’s mechanism of action?

Vorapaxar is an oral PAR-1 (protease-activated receptor-1) antagonist, reducing platelet activation pathways linked to thrombin signaling.

2) Why does ZONTIVITY have constrained adoption?

The product has a clinically significant intracranial hemorrhage risk, which reduces eligibility and willingness to prescribe outside carefully selected cohorts.

3) Does vorapaxar replace standard antiplatelet therapy?

No. It is generally used only in defined secondary-prevention settings within label constraints, while P2Y12 inhibitors and aspirin-based strategies remain the dominant regimens.

4) What is the most important driver of future use?

Patient selection and bleeding-risk management under label-safe interpretation determine whether clinicians keep prescribing.

5) What would change ZONTIVITY’s market trajectory most?

A new label expansion or strong evidence that improves the net clinical benefit in a larger, clearly defined population while mitigating ICH risk.

---

References

[1] FDA. ZONTIVITY (vorapaxar) prescribing information.
[2] FDA. Labeling and regulatory safety information for vorapaxar (PAR-1 antagonist).
[3] TRA 2°P–TIMI 50 trial publication.
[4] TRACER trial publication.